Categories
For Edit

Even as Trump cut immigration, immigrants transformed U.S.

The past four years have seen a steep reduction in immigration. But the country is becoming ever more diverse.

To grasp the impact of the latest great wave of immigration to the United States, consider the city of Grand Island, Neb.: More than 60 percent of public school students are nonwhite, and their families collectively speak 55 languages. During drop-off at Starr Elementary on a recent morning, parents bid their children goodbye in Spanish, Somali and Vietnamese.

“You wouldn’t expect to see so many languages spoken in a school district of 10,000,” said Tawana Grover, the school superintendent who arrived from Dallas four years ago. “When you hear Nebraska, you don’t think diversity. We’ve got the world right here in rural America.”

The students are the children of foreign-born workers who flocked to this town of 51,000 in the 1990s and 2000s to toil in the area’s meatpacking plants, where speaking English was less necessary than a willingness to do the grueling work.

They came to Nebraska from every corner of the globe: Mexicans, Guatemalans and Hondurans who floated across the Rio Grande on inner tubes, in search of a better life; refugees who fled famine in South Sudan and war in Iraq to find safe haven; Salvadorans and Cambodians who spent years scratching for work in California and heard that jobs in Nebraska were plentiful and the cost of living low.

The story of how millions of immigrants since the 1970s have put down lasting roots across the country is by now well-known. What is less understood about President Trump’s four-year-long push to shut the borders and put “America First” is that his quest may prove ultimately a futile one. Even with one of the most severe declines in immigration since the 1920s, the country is on an irreversible course to becoming ever more diverse, and more dependent on immigrants and their children.

The president since the moment he took office issued a torrent of orders that reduced refugee admissions; narrowed who is eligible for asylum; made it more difficult to qualify for permanent residency or citizenship; tightened scrutiny of applicants for high-skilled worker visas and sought to limit the length of stay for international students. His policies slashed the number of migrants arrested and then released into the country from nearly 500,000 in fiscal 2019 to 15,000 in fiscal 2020.

The measures worked: “We are going to end the decade with lower immigration than in any decade since the ’70s,” said William Frey, a senior fellow at the Brookings Institution, who analyzed newly available census data.

The president-elect, Joseph R. Biden Jr. has pledged to reverse many of the measures. He has vowed to reinstate Deferred Action for Childhood Arrivals, known as DACA, an Obama-era program that allowed young adults mainly brought to the United States illegally as children to remain, and to resume accepting refugees and asylum seekers in larger numbers.

He has also said he would introduce legislation to offer a path to citizenship for people in the country illegally.

The foreign-born population grew by 5.6 million in the ’80s, 8.8 million in the ’90s and 11.3 million in the 2000s.

By the time Mr. Trump took office, this contemporary wave of immigration had lifted the foreign-born population to 44.5 million, representing 13.7 percent of the population, the biggest share since 1910. Among them were about 11 million undocumented immigrants.

During his first week in office, the president introduced a travel ban to halt the entry of people from many Muslim countries and paused refugee resettlement, citing terrorist threats.

As Central American migrants fleeing violence and poverty showed up at the border by the busload, his administration introduced policies to deter them, including the separation of migrant children from their parents.

He was able to do it by bypassing a Congress that has long been deadlocked on immigration reform, issuing a series of executive orders and proclamations that rapidly shut the door on immigration despite a flurry of legal challenges.

“Trump has demonstrably proven that you don’t need a grand deal to tackle immigration and border security,” said James Carafano of the Heritage Foundation, a conservative think tank.

Average net migration shrank by 45 percent between 2017 and 2019 from an average of 953,000 during the previous seven years, as fewer immigrants arrived and more left, according to a Center for Immigration Studies analysis of census data.

There will be an even more precipitous decline recorded by the close of 2020 following visa restrictions imposed by the president amid the coronavirus pandemic.

“This year is truly unprecedented in how dramatic and fast this decline in immigration has been,” said David Bier, an immigration analyst at the libertarian Cato Institute. “Outside of wars and the Great Depression, we have never seen a level of immigration like we are seeing right now.”

Mr. Trump put much of the focus on disparaging refugees and immigrants as drains on public coffers and championing a wall on the southwestern border.

Yet all the attention on the border ignored the much more significant growth in immigration that was happening elsewhere in the country.

The number of immigrants of Asian origin grew by 2.8 million in the nine years ending 2019, more than from any other region. The biggest gains were among Indians and Chinese; the number of Mexicans dropped by 779,000.

Many of the recent immigrants have settled in parts of the country where there is a low concentration of foreign-born people, including in states that voted for Mr. Trump in both 2016 and 2020.

Among them are Shikha Jaiswal, a nephrologist, and her husband, Nihit Gupta, a child and adolescent psychiatrist, who came to the United States from India to complete their residencies and are building their careers in a medically underserved area of West Virginia.

Small-town America has come to rely on a pipeline of foreign doctors. “People have been very kind and grateful at the same time, making it a very rewarding experience,” Dr. Jaiswal said.

The children of immigrants who are already here will continue to make the United States more diverse: The 2020 census is expected to show that more than half of people under 18 are people of color.

“The mainstream now increasingly includes people who are nonwhite, particularly from immigrant backgrounds,” said Richard Alba, a sociology professor at the City University of New York Graduate Center.

The movement of the baby boom generation out of the labor force amid a plummeting birthrate is accelerating the trend and intensifying the need for new immigrant labor to pay the Social Security and Medicare bills for retiring Americans.

“It’s not that native-born kids can’t take the boomers’ jobs; it’s that there are not enough of these kids to take them,” said Dowell Myers, a demographer at the University of Southern California who researches the subject.

That diversity is already being reflected in the higher rungs of the work force.

For much of the second half of the 20th century, white workers held a virtual monopoly on the best-paying positions. But by 2015, among top-earning workers under 50, about a third were nonwhite, mainly Latinos or Asians of immigrant origin, according to research by Mr. Alba, who predicts that their share will only grow.

A study released last month found that nearly 30 percent of all students enrolled in colleges and universities in 2018 hailed from immigrant families, up from 20 percent in 2000.

“When you start having cohorts of college graduates that are so diverse, it’s going to change the work force, which means more people from diverse backgrounds moving into positions of authority and high remuneration,” Mr. Alba said. “There’s no going back.”

 

— NYT: Top Stories

Categories
For Edit

Pfizer’s early data shows vaccine is more than 90% effective

Pfizer announced positive early results from its coronavirus vaccine trial, cementing the lead in a frenzied global race that has unfolded at record-breaking speed.

Wall Street was set to open higher following gains in global markets on the first day of trading since Joe Biden’s election.

 

— NYT: Top Stories

Categories
Healthcare

Bristol Myers Squibb presents late-breaking Phase 2 data demonstrating the safety and efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis

Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints

Deucravacitinib was well-tolerated with a safety profile consistent with prior studies

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ACR20Bristol Myers Squibb (NYSE:BMY) today announced results from an ongoing Phase 2 study evaluating the safety and efficacy of deucravacitinib (BMS-986165) 6 mg or 12 mg once daily, compared with placebo in adults with active psoriatic arthritis. The study met the primary endpoint of at least a 20 percent improvement in signs and symptoms of disease (ACR 20) at Week 16. Patients treated with deucravacitinib 6 mg (n=70) or 12 mg (n=67) demonstrated significantly greater ACR 20 responses versus placebo (n=66) at Week 16 (52.9% and 62.7% versus 31.8%, respectively) (p=0.0134 and p=0.0004, respectively). Treatment with deucravacitinib also led to significant improvements on key secondary endpoints relevant for patients, including improvement from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) and change from baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 Item (SF-36) Questionnaire.

These results (Abstract #L03) will be presented today as part of the Late-Breaking Posters Session from 9:00-11:00 a.m. EST at the American College of Rheumatology (ACR) Convergence 2020.

“The positive data from this Phase 2 study evaluating the safety and efficacy of deucravacitinib support the ongoing evaluation of this novel oral therapy for people living with the debilitating effects of psoriatic arthritis,” said lead study investigator, Philip Mease, M.D., director of rheumatology research at Swedish Medical Center/Providence St. Joseph Health and clinical professor at the University of Washington School of Medicine, Seattle. “Many patients with psoriatic arthritis are not adequately treated, reinforcing the need for safe and effective oral treatment options that may help control the range of symptoms experienced as a result of this disease.”

At Week 16, all key secondary endpoints were achieved, with significant improvements observed in additional secondary endpoints evaluated in the trial. Findings include:

  • Improvement from baseline in the HAQ-DI for deucravacitinib 6 mg and 12 mg (-0.37, -0.39) compared to placebo (-0.11) (p=0.002 and p=0.0008, respectively).
  • Change from baseline in the PCS Score of the SF-36 Questionnaire at Week 16, which was 5.6 and 5.8 for deucravacitinib 6 mg and 12 mg, respectively, versus 2.3 for placebo (p=0.0062 and p=0.0042, respectively).
  • Significantly greater improvements in ACR 50 response for patients treated with deucravacitinib 6 mg or 12 mg (24.3% and 32.8%, respectively) compared to placebo (10.6%) (p=0.0326 and p=0.0016, respectively).
  • Additionally, a significantly greater proportion of patients treated with deucravacitinib 6 mg or 12 mg achieved the following secondary endpoints compared to placebo:
    • HAQ-DI response, defined as achievement of HAQ-DI minimal clinically important difference 0.35 (p=0.0019 and p=0.0015, respectively).
    • Enthesitis resolution (enthesitis occurs when the connective tissue between tendons or ligaments and bone becomes inflamed; measured by the Leeds Index) (p=0.0138 and p=0.0393, respectively).
    • Minimal disease activity (defined as meeting key disease criteria related to joints, skin lesions, pain, global disease activity and health assessment questionnaire scores) (p=0.0119 and p=0.0068, respectively).

In this trial, deucravacitinib was well-tolerated and the safety profile was similar to that observed in the previously reported Phase 2 psoriasis trial. In the study, there were no serious adverse events reported in deucravacitinib-treated patients. The most common treatment-emergent adverse events for patients who received deucravacitinib 6 mg or 12 mg versus placebo, respectively, were nasopharyngitis (5.7%, 17.9%, 7.6%), rash (4.3%, 6.0%, 0%) and headache (7.1%, 1.5%, 4.5%).

“These data, along with the recent positive Phase 3 data evaluating deucravacitinib in patients with moderate to severe plaque psoriasis, support our continued study of deucravacitinib and bring us one step closer to further advancing care for people living with psoriatic disease,” said Mary Beth Harler, M.D., head of Immunology and Fibrosis Development, Bristol Myers Squibb. “As the first and only novel, oral, selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases, deucravacitinib represents Bristol Myers Squibb’s deep scientific commitment to investigating novel targets that may lead to the development of innovative treatments for immune-mediated diseases.”

About the Phase 2 Deucravacitinib Psoriatic Arthritis Trial

The study is an ongoing, one-year, randomized, double-blind, placebo-controlled (initial 16 weeks), multicenter, Phase 2 trial. Eligible patients had a psoriatic arthritis diagnosis for at least 6 months, met Classification for Psoriatic Arthritis (CASPAR) criteria and had active disease (at least 3 tender and at least 3 swollen joints), C reactive protein ≥3 mg/L (ULN, 5 mg/L) and at least 1 psoriatic lesion (≥2 cm). Patients had failed or were intolerant to at least 1 nonsteroidal anti-inflammatory drug, corticosteroid and/or conventional synthetic disease-modifying antirheumatic drug (csDMARD). Patients had failed up to 1 TNF inhibitor (≤30%). Patients were randomized 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo.

The primary endpoint was ACR 20 response at Week 16. Key secondary endpoints included improvement from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) and Short Form-36 Physical Component Score (SF-36 PCS). Additional endpoints included the proportion of patients achieving ACR 50/70, HAQ-DI response (≥0.35 improvement from baseline), minimal disease activity, enthesitis resolution (Leeds Index) and adverse events.

Of 203 patients randomized, 180 (89.0%) completed 16 weeks of treatment. The mean age was 49.8 years, median psoriatic arthritis duration was 4.5 years, 65.0% of patients were using csDMARDs at baseline and 15.8% had failed or were intolerant to TNF inhibitors. More information can be found on www.clinicaltrials.gov (NCT03881059).

About Psoriatic Arthritis

Psoriatic arthritis is a chronic, immune-mediated, heterogenous disease with multiple musculoskeletal and skin manifestations, including inflammatory arthritis, enthesitis (which occurs when the connective tissue between tendons or ligaments and bone becomes inflamed), dactylitis (inflammation of the fingers and toes) and psoriatic skin and nail lesions. Up to 30 percent of patients with psoriasis will develop psoriatic arthritis. In addition to the loss of physical function, pain and fatigue caused by psoriatic arthritis, the disease can significantly impact the mental and emotional well-being of patients. Patients with psoriatic arthritis are also at increased risk of developing serious comorbidities, including cardiovascular disease, metabolic syndrome and depression, as well as extraarticular manifestations of disease, such as inflammatory bowel disease.

About Deucravacitinib

Deucravacitinib (BMS-986165) is the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases. Deucravacitinib’s selectivity is driven by a unique mechanism of action that is distinct from other kinase inhibitors. TYK2 is an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses.

Deucravacitinib is being studied in a wide spectrum of immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. Deucravacitinib is not approved for any use in any country.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results will be consistent with the results to date, that deucravacitinib (BMS-986165) may not receive regulatory approval for the indication described in this release in the currently anticipated timeline or at all and, if approved, whether such product candidate for such indication described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

Contacts

Bristol Myers Squibb

Media Inquiries:

media@bms.com

Kirby Hosea

Kirby.Hosea@bms.com

Investors:

Tim Power

609-252-7509

Timothy.Power@bms.com

Nina Goworek

908-673-9711

Nina.Goworek@bms.com

Categories
Weather

Tropical Storm Eta roars toward Florida as hurricane watches, state of emergency declared

A strengthened Tropical Storm Eta is roaring across Cuba on Sunday with South Florida in its sights next after leaving dozens dead in Central America.

 

— FOX News

Categories
For Edit

Alexandria Ocasio-Cortez on Biden’s win, House losses, and what’s next for the Left

The congresswoman said Joe Biden’s relationship with progressives would hinge on his actions. And she dismissed criticism from House moderates, calling some candidates who lost their races “sitting ducks.”

For months, Representative Alexandria Ocasio-Cortez has been a good soldier for the Democratic Party and Joseph R. Biden Jr. as he sought to defeat President Trump.

But on Saturday, in a nearly hourlong interview shortly after President-elect Biden was declared the winner, Ms. Ocasio-Cortez made clear the divisions within the party that animated the primary still exist. And she dismissed recent criticisms from some Democratic House members who have blamed the party’s left for costing them important seats. Some of the members who lost, she said, had made themselves “sitting ducks.”

Well, I think the central one is that we aren’t in a free fall to hell anymore. But whether we’re going to pick ourselves up or not is the lingering question. We paused this precipitous descent. And the question is if and how we will build ourselves back up.

We know that race is a problem, and avoiding it is not going to solve any electoral issues. We have to actively disarm the potent influence of racism at the polls.

But we also learned that progressive policies do not hurt candidates. Every single candidate that co-sponsored Medicare for All in a swing district kept their seat. We also know that co-sponsoring the Green New Deal was not a sinker. Mike Levin was an original co-sponsor of the legislation, and he kept his seat.

I think it’s going to be really important how the party deals with this internally, and whether the party is going to be honest about doing a real post-mortem and actually digging into why they lost. Because before we even had any data yet in a lot of these races, there was already finger-pointing that this was progressives’ fault and that this was the fault of the Movement for Black Lives.

I’ve already started looking into the actual functioning of these campaigns. And the thing is, I’ve been unseating Democrats for two years. I have been defeating D.C.C.C.-run campaigns for two years. That’s how I got to Congress. That’s how we elected Ayanna Pressley. That’s how Jamaal Bowman won. That’s how Cori Bush won. And so we know about extreme vulnerabilities in how Democrats run campaigns.

— NYT: Top Stories

Categories
For Edit

Biden could roll back Trump agenda with blitz of executive actions

For Joseph R. Biden Jr., who narrowly won the election in a deeply divided nation; the early signals he sends as the country’s new leader will be critical.

— NYT: Top Stories

Categories
For Edit

‘It’s such a relief’: Biden voters rebuild a wall that Trump smashed

Joe Biden’s victory was particularly sweet for supporters in three states he had to win: Pennsylvania, Wisconsin and Michigan.

 Kristyn LaBarge was on a walk when she found out, not from a smartphone alert or a call from a friend but from the loud banging of pots that something significant had happened — that Joseph R. Biden Jr. had made Donald J. Trump a one-term president.

From San Francisco to New York to Washington, D.C., big Democratic cities were erupting with spontaneous street parties of singing, honking and dancing on Saturday. But in Pennsylvania, Michigan and Wisconsin, which catapulted Mr. Trump to the presidency in 2016 and which Mr. Biden had just reclaimed, the celebrations seemed particularly sweet and personal. That was especially true in the leafy suburbs of Philadelphia, where huge Democratic margins had tipped the state that tipped the election.

“It was one of the most phenomenal moments of our lives,” said Ms. LaBarge, a 48-year-old mother of two boys and two girls. She rushed home to find that her son was already blasting the national anthem. In this most bitter of election’s wake, hearing Mr. Biden’s calming tone this week, she said, “was like this sweet music washing over me.”

“It just feels like,” she said, pausing and redirecting. “It’s such a relief.”

 

— New York Times: Top Stories

Categories
For Edit

What happens to the border wall under a President Biden?

President Trump made building a wall on the southern border to stop the flow of illegal immigration one of the his top priorities of his term in office. Now, with a considerable stretch built, what happens to the wall when President-elect Joe Biden takes office?

 

— FOX News

Categories
For Edit

Biden, in victory tweet, promises to be ‘President for All Americans – whether you voted for me or not’

In a victory tweet after Joe Biden was projected to become the next president of the U.S., the former vice president promised to be “President for all Americans.”

 

— FOX News

Categories
For Edit

Kamala Harris makes history as first woman and woman of color as vice president

Ms. Harris, the daughter of an Indian mother and Jamaican father, has risen higher in the country’s leadership than any woman ever before her.

— New York Times: Top Stories